{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T18:05:53Z","timestamp":1758823553469},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0105091","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T14:58:46Z","timestamp":1408028326000},"page":"e105091","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy"],"prefix":"10.1371","volume":"9","author":[{"given":"Chien-Hua","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Ton","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong-Shiau","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Chiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0889-8588(05)70364-6","article-title":"How is androgen-dependent metastatic prostate cancer best treated?","volume":"10","author":"M Robson","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"N Sharifi","year":"2005","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x","article-title":"Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group","volume":"79","author":"RS Adib","year":"1997","journal-title":"Br J Urol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/03000605900180S114","article-title":"Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group","volume":"18","author":"H Akaza","year":"1990","journal-title":"J Int Med Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/03000605900180S116","article-title":"Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial","volume":"18","author":"M Rizzo","year":"1990","journal-title":"J Int Med Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"J Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000019546","article-title":"Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center","volume":"33","author":"LJ Denis","year":"1998","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"MA Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-5347(17)36003-2","article-title":"Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial","volume":"149","author":"RA Janknegt","year":"1993","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.2007.13.6804","article-title":"Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer","volume":"26","author":"RW Ross","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"RW Ross","year":"2008","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"NL Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"DF Gleason","year":"1974","journal-title":"J Urol"},{"key":"ref15","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel","volume":"37","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"AJ Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/pros.21174","article-title":"Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu","volume":"70","author":"I Takizawa","year":"2010","journal-title":"Prostate"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/pros.21334","article-title":"Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy","volume":"71","author":"SP Huang","year":"2011","journal-title":"Prostate"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00432-010-0877-9","article-title":"Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer","volume":"137","author":"S Hori","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref20","unstructured":"Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ,<etal>et al<\/etal>.. (2012) Detectable Prostate-Specific Antigen Nadir During Androgen-Deprivation Therapy Predicts Adverse Prostate Cancer-Specific Outcomes: Results from the SEARCH Database. Eur Urol pii: S0302-2838(12)01437-6."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.urology.2008.01.026","article-title":"Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups","volume":"72","author":"CH Chen","year":"2008","journal-title":"Urology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.juro.2006.11.054","article-title":"Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study","volume":"177","author":"JN Graff","year":"2007","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cncr.23106","article-title":"Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent","volume":"112","author":"MW Kattan","year":"2008","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.ijrobp.2012.08.036","article-title":"PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era","volume":"85","author":"SE McGuire","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0090-4295(02)01633-3","article-title":"Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era","volume":"60","author":"MG Oefelein","year":"2002","journal-title":"Urology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","article-title":"Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning","volume":"169","author":"TR Glass","year":"2003","journal-title":"J Urol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdp365","article-title":"Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy","volume":"21","author":"R de Crevoisier","year":"2010","journal-title":"Ann Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.24064","article-title":"Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy","volume":"115","author":"TK Choueiri","year":"2009","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/pcan.2011.14","article-title":"Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis","volume":"14","author":"T Sasaki","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12032-013-0719-0","article-title":"Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy","volume":"30","author":"BM Thomas","year":"2013","journal-title":"Med Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13685538.2011.580398","article-title":"Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy","volume":"15","author":"SP Huang","year":"2012","journal-title":"Aging Male"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.urology.2007.01.087","article-title":"Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure","volume":"69","author":"MH Radwan","year":"2007","journal-title":"Urology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1078-1439(03)00057-7","article-title":"Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)","volume":"21","author":"D Cho","year":"2003","journal-title":"Urol Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00005392-199707000-00052","article-title":"Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2","volume":"158","author":"T J\u00f8rgensen","year":"1997","journal-title":"J Urol"},{"key":"ref35","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, <etal>et al<\/etal>.. (2012) SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations). National Cancer Institute, Bethesda."},{"key":"ref36","unstructured":"National Cancer Registry (2009) Annual Report of Taiwan Cancer Registry. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/crs.cph.ntu.edu.tw\/uploadimages\/Y95-C185_7.pdf\" xlink:type=\"simple\">http:\/\/crs.cph.ntu.edu.tw\/uploadimages\/Y95-C185_7.pdf<\/ext-link>. Accessed 28 May 2009."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1097-0142(197908)44:2<763::AID-CNCR2820440251>3.0.CO;2-5","article-title":"Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate","volume":"44","author":"WR Berry","year":"1979","journal-title":"Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-012-1351-7","article-title":"The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review","volume":"139","author":"N Kachroo","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref39","first-page":"5173","article-title":"Prognostic factors in patients with advanced stage prostate cancer","volume":"45","author":"LJ Emrich","year":"1985","journal-title":"Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0105091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:51:53Z","timestamp":1588971113000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0105091"}},"subtitle":[],"editor":[{"given":"Chih-Pin","family":"Chuu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0105091","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}